Charmie K. Vang
Charmie K. Vang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jane E. Gross
Department of Pediatrics, University of North Carolina , Chapel Hill, North Carolina
4 shared publications - Evan Pierce Brenner
Department of Biomedical Informatics, Center for Health Artificial Intelligence, University of Colorado Anschutz , Aurora, CO 80045
3 shared publications - Janani Ravi
Department of Biomedical Informatics, Center for Health Artificial Intelligence, University of Colorado Anschutz , Aurora, CO 80045
3 shared publications - Jerry A. Nick
Department of Medicine, National Jewish Health, Denver, CO, USA
3 shared publications - Matthew Strand
National Jewish Health, Division of Biostatistics, USA
3 shared publications - Silvia M. Caceres
Department of Medicine, National Jewish Health, Denver, CO 80206, USA
3 shared publications
Latest Publications
- Open Access
amR: an R package suite to predict antimicrobial resistance in bacterial pathogens
Motivation: Identifying bacterial antimicrobial resistance (AMR) is critical for diagnostics and treatment, but resistance is a complex trait arising from myriad mechanisms spanning multiple molecular scales. Existing computational approaches often function as black boxes and rarely explore cross-species or multi-drug patterns. We developed amR, an integrated R package suite that provides a complete framework from bacterial genome data curation to interpretable AMR predictions, enabling identification of resistance mechanisms across species and drugs. Results: The amR R package suite contains three modular packages. amRdata downloads genomes and paired antimicrobial susceptibility testing data from BV-BRC and processes them, constructs pangenomes, and extracts features at gene/protein cluster, protein domain, annotated Clusters of Orthologous Groups and ResFinder AMR-associated features, and structural variant scales; data are stored in memory-efficient formats (Parquet, DuckDB). amRml trains interpretable machine learning models per species-drug combination, calculates feature importance and performance metrics, and provides rich ground for hypothesis generation and mechanism discovery. amRviz provides an interactive Shiny dashboard to explore metadata distributions and model performance across species and drugs, visualize top predictive AMR features, and analyze cross-model patterns across geographic/temporal strata. We apply the suite to Shigella sonnei, achieving a median Matthews Correlation Coefficient of 0.89 across 23 drugs and drug classes. With thousands of genomes, multi-scale features, and interpretable models, amR provides an accessible, comprehensive framework for AMR research. The amR package suite is installable via GitHub (https://github.com/JRaviLab/amR; BSD-3-Clause license).
Open AccessamR: an R package suite to predict antimicrobial resistance in bacterial pathogens
Motivation: Identifying bacterial antimicrobial resistance (AMR) is critical for diagnostics and treatment, but resistance is a complex trait arising from myriad mechanisms spanning multiple molecular scales. Existing computational approaches often function as black boxes and rarely explore cross-species or multi-drug patterns. We developed amR, an integrated R package suite that provides a complete framework from bacterial genome data curation to interpretable AMR predictions, enabling identification of resistance mechanisms across species and drugs. Results: The amR R package suite contains three modular packages. amRdata downloads genomes and paired antimicrobial susceptibility testing data from BV-BRC and processes them, constructs pangenomes, and extracts features at gene/protein cluster, protein domain, annotated Clusters of Orthologous Groups and ResFinder AMR-associated features, and structural variant scales; data are stored in memory-efficient formats (Parquet, DuckDB). amRml trains interpretable machine learning models per species-drug combination, calculates feature importance and performance metrics, and provides rich ground for hypothesis generation and mechanism discovery. amRviz provides an interactive Shiny dashboard to explore metadata distributions and model performance across species and drugs, visualize top predictive AMR features, and analyze cross-model patterns across geographic/temporal strata. We apply the suite to Shigella sonnei, achieving a median Matthews Correlation Coefficient of 0.89 across 23 drugs and drug classes. With thousands of genomes, multi-scale features, and interpretable models, amR provides an accessible, comprehensive framework for AMR research. The amR package suite is installable via GitHub (https://github.com/JRaviLab/amR; BSD-3-Clause license).
- Open Access
Genotype-phenotype modeling of light ecotypes in Prochlorococcus reveals genomic signatures of ecotypic divergence
Prochlorococcus species are the most abundant marine photosynthetic bacteria. Despite broadly shared phenotypic traits and marine habitats, they exhibit remarkable genomic diversity. We ask what genomic signatures underlie its ecotypic divergence into high- and low-light adapted lineages, and whether these signatures can still be recovered from incomplete assemblies. From ∼1,000 publicly available Prochlorococcus genomes, we focused on those with information on their light adaptation ecotype (high-light/low-light), phylogenetic clades, and depth of isolation. Across these divisions, we calculated average nucleotide identity and constructed pangenomes to assess cyanobacterial core genes vs. those that separate ecotypes. Despite scant conservation, we observe a sharp taxon separation by light ecotypes. Classical machine learning models trained to predict ecotype achieve near-perfect binary classification accuracy even when predicting on partial genomes (Matthews Correlation Coefficient = 0.86 – 1.00), while regression models trained to predict the depth of isolation performed poorly, with high root mean square error values (37.6 – 42.0m). For ecotype prediction, we analyzed top gene features across model runs and classes; these features included photosynthesis-associated genes and pathways, as well as many novel markers of unknown function. When separating ecotypes further by previously described phylogenetic clades, genomic content and composition show even clearer separation among clades, supporting the taxonomic breadth of the Prochlorococcus collective. These results emphasize the genomic specialization underlying ecotypic divergence and support the utility of ML approaches for cyanobacterial ecotype prediction from metagenomic data. Expanded sampling will yield novel clade-specific biology. All data, models, and results are available on GitHub: https://github.com/JRaviLab/cyano_adaptation . Importance: Prochlorococcus are common aquatic cyanobacteria that can derive energy from light. They can be classified into high-/low-light ecotypes depending on how they use light. Prochlorococcus have small genomes compared to other bacteria, but the gene sets they carry are also remarkably flexible, which may help them survive and adapt to their harsh oceanic environment. We studied hundreds of Prochlorococcus genomes from around the world in an effort to predict ecotypes from partial genome sequences. We used comparative genomics, machine learning, and other statistical methods to identify genomic features associated with ecotypes. These statistical approaches predicted ecotypes accurately, reliably, and according to large differences in gene content and genome structure. Our results support that Prochlorococcus can be divided into different species or genera based on clades, and provide many gene targets for further research to understand cyanobacterial circadian rhythms or improve their bioengineering potential as chassis organisms.
Open AccessGenotype-phenotype modeling of light ecotypes in Prochlorococcus reveals genomic signatures of ecotypic divergence
Prochlorococcus species are the most abundant marine photosynthetic bacteria. Despite broadly shared phenotypic traits and marine habitats, they exhibit remarkable genomic diversity. We ask what genomic signatures underlie its ecotypic divergence into high- and low-light adapted lineages, and whether these signatures can still be recovered from incomplete assemblies. From ∼1,000 publicly available Prochlorococcus genomes, we focused on those with information on their light adaptation ecotype (high-light/low-light), phylogenetic clades, and depth of isolation. Across these divisions, we calculated average nucleotide identity and constructed pangenomes to assess cyanobacterial core genes vs. those that separate ecotypes. Despite scant conservation, we observe a sharp taxon separation by light ecotypes. Classical machine learning models trained to predict ecotype achieve near-perfect binary classification accuracy even when predicting on partial genomes (Matthews Correlation Coefficient = 0.86 – 1.00), while regression models trained to predict the depth of isolation performed poorly, with high root mean square error values (37.6 – 42.0m). For ecotype prediction, we analyzed top gene features across model runs and classes; these features included photosynthesis-associated genes and pathways, as well as many novel markers of unknown function. When separating ecotypes further by previously described phylogenetic clades, genomic content and composition show even clearer separation among clades, supporting the taxonomic breadth of the Prochlorococcus collective. These results emphasize the genomic specialization underlying ecotypic divergence and support the utility of ML approaches for cyanobacterial ecotype prediction from metagenomic data. Expanded sampling will yield novel clade-specific biology. All data, models, and results are available on GitHub: https://github.com/JRaviLab/cyano_adaptation . Importance: Prochlorococcus are common aquatic cyanobacteria that can derive energy from light. They can be classified into high-/low-light ecotypes depending on how they use light. Prochlorococcus have small genomes compared to other bacteria, but the gene sets they carry are also remarkably flexible, which may help them survive and adapt to their harsh oceanic environment. We studied hundreds of Prochlorococcus genomes from around the world in an effort to predict ecotypes from partial genome sequences. We used comparative genomics, machine learning, and other statistical methods to identify genomic features associated with ecotypes. These statistical approaches predicted ecotypes accurately, reliably, and according to large differences in gene content and genome structure. Our results support that Prochlorococcus can be divided into different species or genera based on clades, and provide many gene targets for further research to understand cyanobacterial circadian rhythms or improve their bioengineering potential as chassis organisms.
- Open Access
- 8 August 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (6) , 1114-1123
Genomic and epidemiologic investigation of Mycobacterium abscessus isolates in a cystic fibrosis center to determine potential routes of transmission
- 8 August 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (6) , 1114-1123
Open AccessGenomic and epidemiologic investigation of Mycobacterium abscessus isolates in a cystic fibrosis center to determine potential routes of transmission
- Open Access
From sequence to signature: Machine learning uncovers multiscale feature landscapes that predict AMR across ESKAPE pathogens
Since the clinical introduction of antibiotics in the 1940s, antimicrobial resistance (AMR) has become an increasingly dire threat to global public health. Pathogens acquire AMR much faster than we discover new drugs (antibiotics), warranting innovative methods to better understand its molecular underpinnings. Traditional approaches for detecting AMR in novel bacterial strains are time-consuming and labor-intensive. However, advances in sequencing technology offer a plethora of bacterial genome data, and computational approaches like machine learning (ML) provide an optimistic scope for in silico AMR prediction. Here, we introduce a comprehensive multiscale ML approach to predict AMR phenotypes and identify AMR molecular features associated with a single drug or drug family, stratified by time and geographical locations. As a case study, we focus on a subset of the World Health Organization’s Bacterial Priority Pathogens, the frequently drug-resistant and nosocomial ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. We started with sequenced genomes with lab-derived AMR phenotypes, constructed pangenomes, clustered gene and protein sequences, and extracted protein domains to generate pangenomic features across molecular scales. To uncover the molecular mechanisms behind drug-/drug class-specific resistance, we trained logistic regression ML models on our datasets. These yielded ranked lists of AMR-associated genes, proteins, and domains. In addition to recapitulating known AMR features, our models identified novel candidates for experimental validation. The models were performant across molecular scales, data types, and drugs while achieving a median normalized Matthews correlation coefficient of 0.89. Prediction performance showed resilience even when evaluated on geographical and temporal holdouts. We also evaluated model generalizability and cross-resistance across the drug-/drug class-specific models cross-tested on other available drug-/drug class genomes. Finally, we uncovered multiple drug class resistance features using multiclass and multilabel models. Our holistic approach promises reliable prediction of existing and developing resistance in newly sequenced pathogen genomes, while pinpointing the mechanistic molecular contributors of AMR. All our models and results are available at our interactive web app, https://jravilab.org/amr .
Open AccessFrom sequence to signature: Machine learning uncovers multiscale feature landscapes that predict AMR across ESKAPE pathogens
Since the clinical introduction of antibiotics in the 1940s, antimicrobial resistance (AMR) has become an increasingly dire threat to global public health. Pathogens acquire AMR much faster than we discover new drugs (antibiotics), warranting innovative methods to better understand its molecular underpinnings. Traditional approaches for detecting AMR in novel bacterial strains are time-consuming and labor-intensive. However, advances in sequencing technology offer a plethora of bacterial genome data, and computational approaches like machine learning (ML) provide an optimistic scope for in silico AMR prediction. Here, we introduce a comprehensive multiscale ML approach to predict AMR phenotypes and identify AMR molecular features associated with a single drug or drug family, stratified by time and geographical locations. As a case study, we focus on a subset of the World Health Organization’s Bacterial Priority Pathogens, the frequently drug-resistant and nosocomial ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. We started with sequenced genomes with lab-derived AMR phenotypes, constructed pangenomes, clustered gene and protein sequences, and extracted protein domains to generate pangenomic features across molecular scales. To uncover the molecular mechanisms behind drug-/drug class-specific resistance, we trained logistic regression ML models on our datasets. These yielded ranked lists of AMR-associated genes, proteins, and domains. In addition to recapitulating known AMR features, our models identified novel candidates for experimental validation. The models were performant across molecular scales, data types, and drugs while achieving a median normalized Matthews correlation coefficient of 0.89. Prediction performance showed resilience even when evaluated on geographical and temporal holdouts. We also evaluated model generalizability and cross-resistance across the drug-/drug class-specific models cross-tested on other available drug-/drug class genomes. Finally, we uncovered multiple drug class resistance features using multiclass and multilabel models. Our holistic approach promises reliable prediction of existing and developing resistance in newly sequenced pathogen genomes, while pinpointing the mechanistic molecular contributors of AMR. All our models and results are available at our interactive web app, https://jravilab.org/amr .
- 9 June 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22, S104
P131 Investigation of healthcare-associated links in transmission of nontuberculous mycobacteria (HALT NTM)
- 9 June 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22, S104
P131 Investigation of healthcare-associated links in transmission of nontuberculous mycobacteria (HALT NTM)
- Open Access
- 20 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261628
Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design
Background: Healthcare-associated transmission of nontuberculous mycobacteria (NTM) among people with cystic fibrosis (pwCF) has been reported and is of increasing concern. No standardized epidemiologic investigation tool has been published for healthcare-associated NTM outbreak investigations. This report describes the design of an ongoing observational study to standardize the approach to NTM outbreak investigation among pwCF. Methods: This is a parallel multi-site study of pwCF within a single Center who have respiratory NTM isolates identified as being highly-similar. Participants have a history of positive airway cultures for NTM, receive care within a single Center, and have been identified as part of a possible outbreak based on genomic analysis of NTM isolates. Participants are enrolled in the study over a 3-year period. Primary endpoints are identification of a shared healthcare-associated encounter(s) among patients in a Center and identification of environmental isolates that are genetically highly-similar to respiratory isolates recovered from pwCF. Secondary endpoints include characterization of potential transmission modes and settings, as well as incidence and prevalence of healthcare-associated environmental NTM species/subspecies by geographical region. Discussion: We hypothesize that genetically highly-similar strains of NTM among pwCF cared for at the same Center may arise from healthcare sources including patient-to-patient transmission and/or acquisition from environmental sources. This novel study design will establish a standardized, evidence-based epidemiologic investigation tool for healthcare-associated NTM outbreak investigation within CF Care Centers, will broaden the scope of independent outbreak investigations and demonstrate the frequency and nature of healthcare-associated NTM transmission in CF Care Centers nationwide. Furthermore, it will provide valuable insights into modeling risk factors associated with healthcare-associated NTM transmission and better inform future infection prevention and control guidelines. This study will systematically characterize clinically-relevant NTM isolates of CF healthcare environmental dust and water biofilms and set the stage to describe the most common environmental sources within the healthcare setting harboring clinically-relevant NTM isolates. Trial registration: ClinicalTrials.gov NCT04024423. Date of registry July 18, 2019.
- 20 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261628
Open AccessHealthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design
Background: Healthcare-associated transmission of nontuberculous mycobacteria (NTM) among people with cystic fibrosis (pwCF) has been reported and is of increasing concern. No standardized epidemiologic investigation tool has been published for healthcare-associated NTM outbreak investigations. This report describes the design of an ongoing observational study to standardize the approach to NTM outbreak investigation among pwCF. Methods: This is a parallel multi-site study of pwCF within a single Center who have respiratory NTM isolates identified as being highly-similar. Participants have a history of positive airway cultures for NTM, receive care within a single Center, and have been identified as part of a possible outbreak based on genomic analysis of NTM isolates. Participants are enrolled in the study over a 3-year period. Primary endpoints are identification of a shared healthcare-associated encounter(s) among patients in a Center and identification of environmental isolates that are genetically highly-similar to respiratory isolates recovered from pwCF. Secondary endpoints include characterization of potential transmission modes and settings, as well as incidence and prevalence of healthcare-associated environmental NTM species/subspecies by geographical region. Discussion: We hypothesize that genetically highly-similar strains of NTM among pwCF cared for at the same Center may arise from healthcare sources including patient-to-patient transmission and/or acquisition from environmental sources. This novel study design will establish a standardized, evidence-based epidemiologic investigation tool for healthcare-associated NTM outbreak investigation within CF Care Centers, will broaden the scope of independent outbreak investigations and demonstrate the frequency and nature of healthcare-associated NTM transmission in CF Care Centers nationwide. Furthermore, it will provide valuable insights into modeling risk factors associated with healthcare-associated NTM transmission and better inform future infection prevention and control guidelines. This study will systematically characterize clinically-relevant NTM isolates of CF healthcare environmental dust and water biofilms and set the stage to describe the most common environmental sources within the healthcare setting harboring clinically-relevant NTM isolates. Trial registration: ClinicalTrials.gov NCT04024423. Date of registry July 18, 2019.